GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Steminent Biotherapeutics Inc (ROCO:7729) » Definitions » Liabilities-to-Assets

Steminent Biotherapeutics (ROCO:7729) Liabilities-to-Assets : 0.19 (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Steminent Biotherapeutics Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Steminent Biotherapeutics's Total Liabilities for the quarter that ended in Dec. 2024 was NT$81.97 Mil. Steminent Biotherapeutics's Total Assets for the quarter that ended in Dec. 2024 was NT$436.66 Mil. Therefore, Steminent Biotherapeutics's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2024 was 0.19.


Steminent Biotherapeutics Liabilities-to-Assets Historical Data

The historical data trend for Steminent Biotherapeutics's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Steminent Biotherapeutics Liabilities-to-Assets Chart

Steminent Biotherapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Liabilities-to-Assets
1.13 0.13 0.31 0.17 0.19

Steminent Biotherapeutics Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Liabilities-to-Assets Get a 7-Day Free Trial 0.31 0.20 0.17 0.16 0.19

Competitive Comparison of Steminent Biotherapeutics's Liabilities-to-Assets

For the Biotechnology subindustry, Steminent Biotherapeutics's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Steminent Biotherapeutics's Liabilities-to-Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Steminent Biotherapeutics's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Steminent Biotherapeutics's Liabilities-to-Assets falls into.


;
;

Steminent Biotherapeutics Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Steminent Biotherapeutics's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2024 is calculated as:

Liabilities-to-Assets (A: Dec. 2024 )=Total Liabilities/Total Assets
=81.965/436.661
=0.19

Steminent Biotherapeutics's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2024 is calculated as

Liabilities-to-Assets (Q: Dec. 2024 )=Total Liabilities/Total Assets
=81.965/436.661
=0.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Steminent Biotherapeutics  (ROCO:7729) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


Steminent Biotherapeutics Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of Steminent Biotherapeutics's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Steminent Biotherapeutics Business Description

Traded in Other Exchanges
N/A
Address
No.16,Wenhu Street, Neihu District, Taipei, TWN, 11445
Steminent Biotherapeutics Inc is a international stem cell biopharmaceutical company which has stable and efficient stem cell platform technology, aiming to develop live cell drugs to treat degenerative diseases as well as acute and life-threatening diseases. With its Stemchymal which is proprietary technology platform generating the standardized, clinical grade, allogeneic stem cells isolated from human adipose tissue. It is operated in strict compliance to regulations of Taiwan, the US, and Japan.

Steminent Biotherapeutics Headlines

No Headlines